WESTON, Fla., Sept. 14, 2021 /PRNewswire/ -- Cantex Pharmaceuticals, Inc. ("Cantex") today announced that it has sold 6.5 million shares of Chimerix, Inc. in brokerage transactions at a price of $5.75 per share, less brokerage commissions and fees.

About Cantex Pharmaceuticals
Cantex Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on the transformation of known drugs into innovative products with blockbuster potential. Cantex is currently developing novel cancer treatments. Cantex's pipeline consists of three product candidates in Phase 2 and Phase 3 development for diseases with significant unmet medical needs: Azeliragon for life-threatening and disabling complications of cancer, Dicopp^® for hematologic malignancies, and DSTAT, licensed to Chimerix, Inc., as a first-line therapy of acute myeloid leukemia. For more information, please visit www.cantex.com.

More on S For Story

• Atlanta Teen Author and #1 Top New Release Sarai Lokey Takes "Holy Rebel" Straight To The Top!
• The Inner Power of Emotional Self-Leadership
• Dr. Nadene Rose Shares the Secret to True Success: Faith, Obedience, and Divine Purpose
• eBook Publishing Services in USA California Book Publishers Helps Authors Turn Ideas into Successful
• Understanding Unexpected Death: Why Independent Autopsies Matter in Cases Without Clear Cause

Cantex Contacts
Investors:
Stephen G. Marcus, M.D.
(954) 315-3660
[email protected]

or

Media:
Jason Rando
Tiberend Strategic Advisors
(917) 930-6346
[email protected]

SOURCE Cantex Pharmaceuticals, Inc.

---

Show All News | Report Violation